Contributions
Abstract: PB1404
Type: Publication Only
Session title: Acute myeloid leukemia - Clinical
Background
Acute myeloid leukemia (AML) is a disease affecting older patients with a median age of 67 years. Because of age, comorbidities and unfavorable cytogenetics, older patients are frequently not eligible to the standard 7+3 induction chemotherapy combining aracytine and an anthracycline. Their survival remains poor.There is a growing need to better understand the current treatment patterns and their associated outcomes since the field of AML is evolving with the emergence of newer agents.
Aims
To describe treatment patterns and clinical outcomes including survival and remission rates, clinic-pathological characteristics and healthcare resource utilization of AML patients who are unfit to receive intensive chemotherapy in the Belgian real world clinical practice.
Methods
This retrospective chart review was conducted in 6 centers across Belgium. Adult patients who were deemed ineligible for intensive chemotherapy and that have started a systemic treatment or best supportive care between 1st of January 2015 and 31th of December 2018 in the first line setting were included. Patients were followed until death or last recorded contact, whichever came first at time of data collection. Primary objective was to evaluate the overall survival of these patients in the real-world setting. Secondary objectives included but were not limited to progression free survival, time to treatment failure and healthcare resource utilization.
Results
In this Belgian sub analysis, 43 patients were included (65% male, 35% female and 65% >75 years old) of whom 37 (86%) received systemic treatments (29,7% azacitidine, 62,2% decitabine and 8,1% other systemic treatment) and 6 (14%) received Best supportive care including transfusions, pain relief and infection management. Median OS in the overall population was 8,5 months (respectively 9,76 months, 6,74 months and 4,77 months in patients who were treated with hypomethylating agents, other systemic treatment, or best supportive care). A CR/CRI was achieved in 29% of the patients who received systemic treatment, median time to best response was 129,5 days, median duration of the complete response was 458,5 days. During the first course of systemic treatment 34/37 patients were hospitalized due to treatment administration-related (45,5%) and infections (38,1%).
Conclusion
This Belgian sub analysis of the real-world study shows that OS and CR/CRi rates reported are consistent with previous clinical trials but that outcomes for this patient population remain poor. Future combination therapies with HMA or new agents will hopefully improve their outcome.
Keyword(s): Acute myeloid leukemia, AML
Abstract: PB1404
Type: Publication Only
Session title: Acute myeloid leukemia - Clinical
Background
Acute myeloid leukemia (AML) is a disease affecting older patients with a median age of 67 years. Because of age, comorbidities and unfavorable cytogenetics, older patients are frequently not eligible to the standard 7+3 induction chemotherapy combining aracytine and an anthracycline. Their survival remains poor.There is a growing need to better understand the current treatment patterns and their associated outcomes since the field of AML is evolving with the emergence of newer agents.
Aims
To describe treatment patterns and clinical outcomes including survival and remission rates, clinic-pathological characteristics and healthcare resource utilization of AML patients who are unfit to receive intensive chemotherapy in the Belgian real world clinical practice.
Methods
This retrospective chart review was conducted in 6 centers across Belgium. Adult patients who were deemed ineligible for intensive chemotherapy and that have started a systemic treatment or best supportive care between 1st of January 2015 and 31th of December 2018 in the first line setting were included. Patients were followed until death or last recorded contact, whichever came first at time of data collection. Primary objective was to evaluate the overall survival of these patients in the real-world setting. Secondary objectives included but were not limited to progression free survival, time to treatment failure and healthcare resource utilization.
Results
In this Belgian sub analysis, 43 patients were included (65% male, 35% female and 65% >75 years old) of whom 37 (86%) received systemic treatments (29,7% azacitidine, 62,2% decitabine and 8,1% other systemic treatment) and 6 (14%) received Best supportive care including transfusions, pain relief and infection management. Median OS in the overall population was 8,5 months (respectively 9,76 months, 6,74 months and 4,77 months in patients who were treated with hypomethylating agents, other systemic treatment, or best supportive care). A CR/CRI was achieved in 29% of the patients who received systemic treatment, median time to best response was 129,5 days, median duration of the complete response was 458,5 days. During the first course of systemic treatment 34/37 patients were hospitalized due to treatment administration-related (45,5%) and infections (38,1%).
Conclusion
This Belgian sub analysis of the real-world study shows that OS and CR/CRi rates reported are consistent with previous clinical trials but that outcomes for this patient population remain poor. Future combination therapies with HMA or new agents will hopefully improve their outcome.
Keyword(s): Acute myeloid leukemia, AML